title: Immunomodulatory antibody therapy of cancer: the closer, the better.
abstract: Immune checkpoint blockade therapies have demonstrated promising therapeutic effects; however, clinical outcomes are variable, with only a subgroup of cancer patients achieving durable complete responses. New therapeutic strategies, including local administration of immunomodulatory antibodies, have been considered as better routes for improving the overall efficacy of antibody-based therapy.
authors.affiliation: Division of Medical Oncology, College of Medicine, Mayo Clinic, Rochester, Minnesota.
authors.forename: Roxana S
authors.initials: RS
authors.lastname: Dronca
authors.affiliation: Department of Urology, College of Medicine, Mayo Clinic, Rochester, Minnesota. Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota. dong.haidong@mayo.edu.
authors.forename: Haidong
authors.initials: H
authors.lastname: Dong
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019013:CD40 Antigens / Q000819:agonists*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology*; D013601:T-Lymphocytes / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D019013:CD40 Antigens; D007155:Immunologic Factors; C000602878:mitazalimab